Transjugular Intrahepatic Portosystemic Shunt Is Associated With Better Waitlist Management of Liver Transplant Candidates With Hepatocellular Carcinoma.
Humans
Carcinoma, Hepatocellular
/ surgery
Liver Transplantation
Waiting Lists
/ mortality
Liver Neoplasms
/ surgery
Portasystemic Shunt, Transjugular Intrahepatic
Male
Female
Middle Aged
Aged
Propensity Score
alpha-Fetoproteins
/ analysis
Adult
Hypertension, Portal
/ surgery
Retrospective Studies
Treatment Outcome
Registries
hepatocellular carcinoma
liver transplantation
progression
recurrence
survival
Journal
Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516
Informations de publication
Date de publication:
2024
2024
Historique:
received:
31
01
2024
accepted:
12
06
2024
medline:
24
7
2024
pubmed:
24
7
2024
entrez:
24
7
2024
Statut:
epublish
Résumé
Transjugular intrahepatic portosystemic shunt (TIPS) reduces portal hypertension complications. Its impact on hepatocellular carcinoma (HCC) remains unclear. We evaluated 42,843 liver transplant candidates with HCC from the Scientific Registry of Transplant Recipients (2002-2022). 4,484 patients with and without TIPS were propensity score-matched 1:3. Analysing wait-list changes in total tumor volume, HCC count, and alpha-fetoprotein levels, and assessing survival from listing and transplantation; TIPS correlated with a decreased nodule count (-0.24 vs. 0.04,
Identifiants
pubmed: 39044902
doi: 10.3389/ti.2024.12781
pii: 12781
pmc: PMC11265282
doi:
Substances chimiques
alpha-Fetoproteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
12781Informations de copyright
Copyright © 2024 El Hajji, Lacotte, Moeckli, Cauchy, Compagnon and Toso.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.